Details of the Drug

General Information of Drug (ID: DMW5V4U)

Drug Name

Enfortumab vedotin

Synonyms

Padcev

Indication

Disease Entry	ICD 11	Status	REF
Urothelial carcinoma	2C92.0	Approved	[1]
Bladder cancer	2C94	Phase 3	[2]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

L01FX13: Enfortumab vedotin

L01FX: Other monoclonal antibodies and antibody drug conjugates

L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Antibody drug conjugate

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nectin cell adhesion molecule 4 (NECTIN4)	TTPO9EG	NECT4_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website.
2	ClinicalTrials.gov (NCT03474107) An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301). U.S.National Institutes of Health.
3	Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022 Mar;72(2):165-182.